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Rare chromosomal deletions and duplications increase risk of
schizophrenia
The International Schizophrenia Consortium1
Schizophrenia (SCZ) is a severe mental disorder marked by hallucinations, delusions,
cognitive deficits and apathy with heritability estimated at 73-90%1. Inheritance patterns are
complex and the number and type of genetic variants involved are not understood. Copy
number variants (CNVs) have been identified in individual SCZ patients2-7 and also in
neurodevelopmental disorders8-11, but large-scale genome-wide surveys have not been
performed. We report such a genome-wide survey of rare CNVs in 3,391 patients with SCZ
and 3,181 ancestrally-matched controls using high-density microarrays. For CNVs that were
observed in less than ∼1% of the sample and greater than 100kb in length, the total burden
is increased in SCZ patients compared to controls (P=3×10−5; 1.15 fold increase). This
effect was more pronounced for rarer, single-occurrence CNVs and for those that involved
genes as opposed to those that did not. As expected, deletions were found within the region
critical for velo-cardio-facial syndrome (P=0.0017, odds ratio (OR) = 21.6), which includes
psychotic symptoms in 30% of patients12. Associations with SCZ were also found for large
deletions on chromosome 15q13.2 (P = 0.0029, OR = 17.9) and 1q21.1 (P = 0.0076, OR =
6.6). These associations were not previously reported in the literature and remained
significant after genome-wide correction. Overall, our results provide strong support for a
model of SCZ pathogenesis that includes the effects of multiple rare structural variants, both
genome-wide and at specific loci.
The International Schizophrenia Consortium (ISC) was established to promote rapid
progress towards the identification of genetic causes underlying SCZ. The ISC is comprised
of investigators from the University of Aberdeen, Cardiff University, the University of
Edinburgh, the Karolinska Institutet, Massachusetts General Hospital, the University of
North Carolina-Chapel Hill, the Queensland Institute of Medical Research, the University of
Southern California, the Stanley Center for Psychiatric Research at the Broad Institute of
Harvard and MIT, Trinity College Dublin and University College London.
We surveyed single nucleotide polymorphisms (SNPs) and CNVs using the Affymetrix
Genome-Wide Human SNP 5.0 and 6.0 Arrays in European SCZ cases and ancestrally-
matched controls (Table 1 and Supplementary Information)13. Based on the genome-wide
SNP data there was no evidence of major population stratification within each site14 (data
not shown). Intensity data from both SNP and CNV probes were used to identify autosomal
deletions and duplications, based on a hidden Markov model (HMM)15.
This study focused on rare but highly penetrant structural variation in schizophrenia,
following a natural extension of the classical medical genetic approach. Common CNVs are
better identified with different algorithms and better tested for association separately13,15.
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Considering CNVs present in less than 1% of our total sample, there were 6,753 greater than
100kb that passed sample and CNV quality filtering (see Supplementary Information, Table
S1). The median size was 182.1kb (166.3kb for deletions, 194.4kb for duplications), 39%
were deletions and the median number per individual was 1. We assessed the impact of rare
structural variation on SCZ risk in two ways: first, in terms of an individual's genome-wide
burden and second, by searching for specific loci that were significantly associated with
disease.
Structural variants have been identified for severe neurodevelopmental disorders9-11,16,17.
Since it has been postulated that SCZ might, at least in part, have a developmental
etiology18, we posited a role for CNVs in SCZ, as have others2-6. A number of loci have in
fact been identified, including variants containing genes with neurodevelopmental roles2-5.
However, a critical question is the extent to which this is a general mechanism for producing
SCZ in typical clinical populations rather than cases selected for atypical phenotypic
features such as very early onset or mental retardation. This motivated our primary
hypothesis: that individuals with SCZ have a greater genome-wide burden of CNVs.
Considering all CNVs, we observed that cases had a greater average burden than controls (1-
sided, empirical P= 3×10−5 controlling for array type; Table 2). Controls on average had
0.99 CNVs per person, whereas cases showed a 1.15-fold higher rate.
We next explored this subtle, but highly statistically significant, observation of increased
burden. We defined burden in two ways: as the number of CNVs an individual carries (as
above), and also as the number of genes spanned by those CNVs. This second metric (the
“gene-count”) in fact showed a stronger association with SCZ (1.41-fold increase, empirical
P=2×10−6) than burden defined simply as the number of CNVs. Characteristics of CNV
subgroups studied here are their frequency, type, size, and proximity to a gene (Tables 2 &
3; Table S2). We observed increased burden across multiple independent subgroups of
CNVs, a finding that was more pronounced for rarer CNVs and those involving genes.
Deletions and duplications also displayed somewhat different profiles: the association of
deletions varied more noticeably with respect to CNV size and proximity to a gene, whereas
duplications showed a more uniform pattern. Eight hundred ninety CNVs were observed in
either a case or a control as a single occurrence. This rarest subset of CNVs would be
expected to show enrichment under the model that genetic causes of SCZ are individually
unique in some proportion of patients. Indeed, this set of CNVs showed a 1.45-fold increase
in cases (empirical P=5×10−6). On average, 13.1% of SCZ cases possessed a deletion or
duplication observed only once in the sample, in contrast to 10.4% of controls. Under a
model in which very rare (occurring in under 1/1000 individuals) inherited or recurrently de
novo events increase risk, we would expect to observe a greater overall burden in SCZ.
Although our study was statistically under-powered to identify the actual loci involved, such
variants could in theory be mapped in extremely large samples. In this intermediate group,
we observed 2,465 CNVs occurring between 2 and 6 times in the total sample, for which
there was an increased burden, both for number of CNVs (empirical P = 0.0013) and gene-
count (empirical P = 5×10−4).
Because several known genomic disorders of the nervous system result from large CNVs,
that are often many hundreds of kilobases11, we additionally stratified by size of event
(Table 3). Of deletions, only larger (>500kb) variants were enriched (empirical P=3×10−4)
despite being the least frequent set of CNVs (N=285), displaying a 3.57-fold increase in
gene-count between cases and controls (empirical P = 2×10−5). In contrast, shorter
duplications showed a stronger association with disease than longer duplications, albeit with
a smaller fold increase than deletions (Table 3).
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In general, the gene-count definition of CNV burden yielded stronger results, particularly for
deletions (gene-count P = 3×10−5 versus number P = 0.11; Table 2). In fact, dividing all
CNVs into two sets, of those that intersect at least one gene and those that do not, we saw an
increased burden only in the number of “genic” CNVs (P = 5×10−6; Table S2) and not for
non-genic CNVs (P = 0.16). There was a similar trend for CNVs seen 2-6 times when
comparing enrichment in genic and non-genic CNVs (P = 7×10−4 and 0.19) but not single-
occurrence CNVs (P=6×10−4 and 6×10−4). These results may reflect biological distinctions,
although they may to some extent also reflect variable performance in CNV detection for
different classes of variant. We conducted a set of analyses to rule out several sources of
bias and confounding in the primary genome-wide burden analysis (Tables S3, S4, S5 &
S6). While, in general, low specificity and sensitivity decrease power, of concern here is
potential measurement error that systematically varied between cases and controls, leading
to spurious results. In this respect, an obvious concern is that both Affymetrix 5.0 and 6.0
arrays were used; as a consequence, we performed all analyses controlling for array type. As
described in the Supplementary Information, the primary result was also robust to the
following. First, in addition to array type, we controlled for sample collection site,
genotyping plate and average probe variance. Second, sensitivity analyses showed that no
single sample collection site accounted for the observations. Third, we restricted analysis to
the most homogeneous 90% of the sample with respect to intra-individual probe variance.
Fourth, if case/control differences in CNV burden were purely due to unmeasured
confounders, we would not expect an enriched gene-count after controlling for the overall
extent and rate of CNVs. Of note, however, is that after controlling for overall (genic and
non-genic) CNV burden there remained a significantly enriched gene-count burden in SCZ
patients.
Our large sample size further enabled us to search for specific CNV regions associated with
SCZ. One locus previously reported to increase risk for SCZ is 22q11.2 (17-21Mb), at which
hemizygosity occurs in 1:4000 live births12. These deletions produce a range of clinically
heterogeneous phenotypes, including velo-cardio facial syndrome (VCFS) and DiGeorge
syndrome that together are known as 22q11.2 deletion syndrome (22q11.2DS)12;
approximately 30% of carriers develop psychosis12. Previous studies estimated the
frequency of 22q11.2 deletions to be 0.6%-1.0% in SCZ cases although many of these
studies had technically incomplete characterization of this region19. Thus we expected to
find examples of 22q11.2 deletions in our sample of 6,572 individuals. The most common
form of 22q11.2DS is a 3Mb loss (∼90% frequency), although a nested 1.5Mb deletion is
also observed (∼7%) along with infrequent (∼3%) atypical deletions20. We identified 13
large deletions (>500 kb) in SCZ cases within this interval and none in controls (Table S7).
Of these, six were consistent with the larger deletion, five with the shorter deletion, and two
were atypical. The 11 samples with typical deletions defined an interval with the strongest
association (empirical P = 0.0017; genome-wide corrected P = 0.0046; odds ratio = 21.6)
(Figure 1A). Controlling for sample collection site or genotyping plate instead of array type
did not change the results (Table S10). The two other atypical deletions in this region
overlap the distal end of the 3Mb variant. Deletion events within the region were confirmed
in all 13 patients by quantitative polymerase chain reaction with three individual assays
(qPCR, Tables S11 & S12 and Figure S1). Our findings provide additional evidence that
hemizygosity in 22q11.2 is a rare but powerful risk factor for SCZ.
The larger 22q11.2 deletion harbors 43 genes (Table S8). Despite the efforts of many
groups, the psychiatric symptoms observed in 22q11DS have not been ascribed to reduced
copy number of any individual gene12. Variants within catechol-O-
methyltransferase(COMT), an enzyme responsible for degrading catecholamines including
dopamine, have been implicated in a wide variety of phenotypes, but with inconsistent
results12.
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Removing the 13 22q11.2DS individuals, we observed a further 271 deletions >500 kb (175
in cases and 110 in controls). Two additional regions (15q13.2 and 1q21.1) were identified
that harbor a significant excess of deletions in SCZ cases after correction for multiple testing
(Figure 1B and 1C; Table S7 for case descriptions). On chromosome 15 (28 – 31Mb) there
were deletions in 9 cases and 0 controls (empirical P = 0.0029; genome-wide corrected P =
0.046; odds ratio = 17.9). On chromosome 1 (142.5-145.5Mb) there were 10 deletions in
cases and 1 in controls (empirical P = 0.0076; genome-wide corrected P = 0.046; odds ratio
= 6.6). All 20 large deletions at 15q13.2 and 1q21.1 were validated by one or more qPCR
reactions (Tables S11 & S12 and Figure S1). The multiple test correction factors were small
as a consequence of restricting our attention to this small class of rare variants. We did not
observe any regions with a corrected P < 0.05 for either duplications or smaller (<500kb)
deletions. Also of note, the primary CNV burden tests remained significant after removing
individuals with a deletion at one of these three loci (number P = 1 × 10−4 and gene-count P
= 3 × 10−5); for >500kb deletions specifically, the burden test remained significant for
number (P = 0.02) but not for gene-count (P = 0.11).
The large deletions on chromosome 15q13.2 have not been previously associated with SCZ.
This region does not include the nearby critical region for Prader-Willi/Angelman
syndrome21 but is consistent with the critical region defined by recurrent deletion in cases of
mental retardation (MR) with seizures recently reported17. Furthermore, our estimated
breakpoints fall within the segmental duplications reported (BP4 and BP5). In the present
study, evidence consistent with mildly-impaired cognition was seen in five of the nine
patients with deletions and one individual also had a history of epilepsy (Table S7). This
broad region has been the focus of previous genetic studies in SCZ. The alpha 7 subunit of
the nicotinic acetylcholine receptor gene (CHRNA7) is a candidate based on an initial
identification from linkage analysis of the P50 auditory evoked potential deficits observed in
SCZ patients22,23 though there are no prior reports of large deletions associated with SCZ.
The deleted region on 1q21.1 is consistent with a previously reported de novo deletion in a
patient with MR and seizures17 and two patients with autism (one de novo and one
inherited)10. In the present study, three cases had mild cognitive abnormalities and one had a
history of epilepsy (Table S7). The region contains 26 known genes, the majority of which
are expressed in the brain (Table S8) and has previous reports of linkage24-26 but no prior
reports of CNVs associated with SCZ.
Regions of highly homologous segmental duplication (SD) flank the deletions we report at
22q11.2, 15q13.2, and 1q21.1. A prominent mechanism for CNV genesis is non-allelic
homologous recombination (NAHR) mediated by SDs, resulting in deletions and reciprocal
duplications of the interval between SDs16,27. Neurodevelopmental and psychiatric
syndromes have been associated with deletions and duplications flanked by SDs, many of
which occur de novo10,11,17. Segmental duplications and NAHR mediate CNVs at 22q11.228
and may be involved in the genesis of CNVs at 15q13.214, and 1q21.1, though other
mechanisms may be involved29. While this work was under review, Walsh et al.2 reported a
higher frequency of CNVs in cases (15%, 22 in 150 SCZ patients) versus controls (5%).
Among the 21 autosomal case CNVs they identified, we observed overlapping control
CNVs at seven loci (for example, DLG2 and PTPRM, Table S9), illustrating that large
sample numbers are needed to conclude that any one particular CNV or implicated gene can
cause SCZ. Our global burden analysis demonstrated that, in aggregate, single-occurrence
and very rare (under ∼1/1000) CNVs have increased rates in SCZ cases compared to
controls, in line with Walsh et al. This suggests that at least some proportion of these rare
CNVs seen in cases but not controls are likely SCZ risk factors, although like Walsh et al,
we are unable to distinguish exactly which. Some examples of possible risk CNVs that were
observed multiple times only in cases include deletions at 12p11.23 (4 cases) and
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16p12.2-12.1 (6 cases). These deletions were >500kb, flanked by SDs and span several
brain-expressed genes. In addition, duplications in two genes relevant to neural development
and growth (NOTCH1 and p21-activated kinase 7, PAK7) were found in 5 and 6 cases
respectively and 0 controls. Furthermore, we identified CNVs at two recently reported loci,
NRXN1 and CNTNAP23,5 (Figure S2).
The etiology of SCZ has been vigorously debated. We now have strong and replicated2
evidence that individuals with SCZ have a greater burden of structural variation across their
genomes. Our data show that CNVs in at least three loci act as strong risk factors for SCZ in
a minority of individuals. Thus we can now posit that some cases of SCZ are “genomic
disorders”16 although we do not yet know whether the risk is specific for SCZ as opposed to
a more general risk factor for neuropsychiatric or central nervous system illness.
Exactly how a subtle, 1.15-fold increase in CNV burden translates mechanistically into
illness in a given patient is currently unknown. We also do not know whether common
genetic variants of more subtle effect are components of the etiology of SCZ, an empirical
question that we and others are addressing. Similarly, we do not know how environmental
risk or protective factors might act in concert with specific CNVs or with overall burden of
CNVs.
A critically important goal will be to determine the full clinical and phenotypic spectrum in
carriers of these deletions. Our data provide preliminary evidence of a variable phenotype in
SCZ patients who would otherwise be regarded as clinically typical. Examining the role of
these variants in related psychotic disorders, such as bipolar disorder, is imperative. Further
work explicating the epidemiology and mechanism of these variants in SCZ may ultimately
lead to a role for them in genetic counseling and understanding disease biology.
Methods Summary
Cases satisfied DSM-IV or ICD-10 criteria for SCZ and were broadly representative of
clinical cases in contact with psychiatric services. DNA was extracted from whole blood,
with approval from institutional review boards. CNVs were identified using the Birdseye
package15 and analysed using PLINK v1.0314. See the Supplementary Information for
detail. A list of all CNVs passing quality control is available at http://pngu.mgh.harvard.edu/
isc/
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Regions with excess large deletions in cases
a)The positions of CNVs >500kb across chromosome 22q11.2 region. Case deletions: red
lines. Horizontal dashed sections: qPCR or visual inspection of array intensity data suggest
an extended deletion. Green lines: locations of low-copy repeats (LCR22-2-LCR22-4). Gray
lines: recurrent ∼3MB and ∼1.5MB VCFS deletions. qPCR primers marked by vertical
dashed lines. b) Chromosome 15q13.2 region, as above, except for the locations of
breakpoint regions (BP4, BP5) (green) and the MR critical region previously defined17. c)
Chromosome 1q21.1: as above, except single deletion identified in a control subject is
marked by blue line.
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Study Sample Characteristics and Genotyping Platforms
Sample Ancestry Case (N) Control (N) Genotyping Platform
University of Aberdeen Scottish 727 694b 5.0
University College London British 547 n/ac 5.0
Portuguese Island Collection Portuguese 333 200b 5.0
Karolinska Institutet Swedish 622 437 5.0/6.0d
Cardiff University Bulgarian 479a 646 6.0
Trinity College Dublin Irish 280 914 6.0
University of Edinburgh Scottish 403a 290 6.0
Number of cases and controls passing quality control and included in the final analyses. Case samples received a diagnosis of schizophrenia by
DSM-IV/ICD-10. Genotyping Platform indicates Affymetrix array type (5.0 or 6.0).
a
Cases were excluded if IQ<70.
b
Controls were excluded for psychiatric disorders.
c
UCL control samples genotyped with the Affymetrix 500K two-chip genotyping platform were excluded as CNV data were not available.
d
Swedish cases and controls matched for array type for all analyses.
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